Clinical pharmaceutics and calcium ceftriaxone [2]

Annals of Pharmacotherapy

Volumn 41, Issue 12, 2007, Pages 2072-

  Rapp, Robert P ^a   Kuhn, Robert ^a  

^a University of Kentucky   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM SALT; CEFOTAXIME; CEFTRIAXONE; CEPHALOSPORIN; RINGER SOLUTION;

ARTERY OCCLUSION; BINDING SITE; CARDIOVASCULAR SYSTEM; CLINICAL PHARMACY; DEATH; DRUG FATALITY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PERSONNEL; HUMAN; HYPERBILIRUBINEMIA; LETTER; LUNG BLOOD VESSEL; NEWBORN; PARTICLE SIZE; PARTICULATE MATTER; PATIENT CARE; PHYSICAL CHEMISTRY; PRECIPITATION; PRIORITY JOURNAL; PROTEIN BINDING; TOTAL PARENTERAL NUTRITION;

ANTI-BACTERIAL AGENTS; ARTERIAL OCCLUSIVE DISEASES; CEFTRIAXONE; CHEMISTRY, PHARMACEUTICAL; HUMANS; INFANT, NEWBORN; PRECIPITATION; SOLUBILITY;

EID: 36849039347     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K410     Document Type: Letter

References (4)

1. Important clarification of prescribing information from Roche Laboratories. August 2007. http://rocheusa.com/products/rocephin/rocephin-hcp- letter.pdf (accessed 2007 Oct 30).
2. Martin E, Fanconi S, Kalin P, et al. Ceftriaxone-bilirubin-albumin interactions in the neonate: an in vivo study. Eur J Pediatr 1993;152:530-4.
3. Ceran C, Oztoprak I, Cankorkmaz L, et al. Ceftriaxone-associated biliary pseudolithiasis in paediatric surgical patients. Int J Antimicrob Agents 2005;25:256-9.
4. Kanke M, Simmons GH, Weiss DL, DeLuca PP. Clearance of 141C-labeled microspheres from blood and distribution in specific organs following intravenous and intraarterial administration to beagle dogs. J Pharm Sci 1980;69:755-62.